A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Ustekinumab-Auub (WEZLANA)

Interleukin-12 Antagonist class · 0 generic manufacturers · 0 ANDAs filed at FDA.

First FDA approval2025-01-01
Generic availableNo (brand-only)
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$5.8M in CY2024 Part D spend283 claims · 199 beneficiaries · 329 plans surveyed

Lowest NADAC
/unit
0 NDCs benchmarked, lowest of all strengths.
Average NADAC
Across all dosage forms in distribution.
Highest NADAC
Range is tight.
Plans with PA
78 / 329
Limited PA friction.

Questions a plan sponsor actually asks.

FAQPage schema10 entries indexed · 4 visible
What is Ustekinumab-Auub used for?

Ustekinumab-Auub is a Interleukin-12 Antagonist medication tracked in Medicare Part D.

Is there a generic for Ustekinumab-Auub?

No. Ustekinumab-Auub is brand-only with no generic equivalents currently in market.

How much does my plan pay for Ustekinumab-Auub?

NADAC pricing data not currently available for this drug.

Is Ustekinumab-Auub on the FDA shortage list?

No. Ustekinumab-Auub is not currently on the FDA Drug Shortage Database.

6 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Interleukin-12 Antagonist5 alternatives in D1
01
Ustekinumab
Brand: STELARA
$2898.19Lowest NADAC
0Generic mfrs
$5.16BCY24 Part D spend
Compare →
02
Ustekinumab-Aauz
Brand: Otulfi
Lowest NADAC
0Generic mfrs
CY24 Part D spend
Compare →
03
Ustekinumab-Aekn
Brand: SELARSDI
Lowest NADAC
0Generic mfrs
$233,857CY24 Part D spend
Compare →
04
Ustekinumab-Hmny
Brand: Starjemza
Lowest NADAC
0Generic mfrs
CY24 Part D spend
Compare →
05
Ustekinumab-Ttwe
Brand: PYZCHIVA
Lowest NADAC
0Generic mfrs
CY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book · NADAC unit costs: CMS NADAC weekly file · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.